Unicycive Therapeutics, Inc. UNCY
Regular-session close
After hours · Nov 19, 7:58 PM ET
- YTD
- -38.82%
- 1 year
- -36.17%
5D -0.11 (-3.03%)
- Market cap
- 103.02M
- EPS (ttm)
- -1.64
- Shares out
- 103.80M
- Forward P/E
- -3.31
- YTD return
- -38.82%
- 1-year return
- -36.17%
- 50-day average
- 0.55888
- 200-day average
- 0.700475
- Volume
- 855.18K
- Avg volume
- 954.65K
- Open
- 3.57
- Previous close
- 3.57
- Day's range
- 3.42 – 3.65
- 52-week range
- 3.33 – 8.74
- Beta
- 2.29
- Price target
- 5.50 (+55.8%)
Key statistics
- Enterprise value
- 47.31M
- Free cash flow
- -16.69M
- Total cash
- 41.78M
- Total debt
- 634.00K
- Return on equity
- -121.76%
- Short % of float
- 1.21%
Fundamental scorecard
5 of 25 checks passed on UNCY’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.13 | -0.05 | +0.08 | +61.54% |
| Aug 14, 2024 | Jun 1, 2024 | -0.23 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.23 | -0.15 | +0.08 | +34.78% |
| May 13, 2024 | Mar 1, 2024 | -0.18 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.18 | -0.27 | -0.09 | -50.00% |
| Mar 28, 2024 | Dec 1, 2023 | -0.18 | -0.16 | +0.02 | +11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 22, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Nov 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 6, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Sep 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- unicycive.com
News
Unicycive Therapeutics Q3 EPS $(0.25) Beats $(0.31) Estimate
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role
Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk
Your note
Sign in to keep a note on UNCY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGGARWAL GAURAV | Director | Conversion of Exercise of derivative security | Oct 8, 2024 | 0 |
| GUPTA PRAMOD | Officer | Conversion of Exercise of derivative security | Jul 10, 2023 | 41,845 |
| GUPTA SHALABH K | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 10, 2023 | 2,527,450 |
| JERMASEK DOUGLAS | Officer | Conversion of Exercise of derivative security | Jul 10, 2023 | 175,012 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Great Point Partners LLC | 8.25% | 8,559,000 | 5.67M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 8.25% | 8,559,000 | 5.67M | Sep 29, 2024 |
| Logos Global Management LP | 4.89% | 5,078,927 | 3.37M | Sep 29, 2024 |
| Walleye Capital LLC | 4.82% | 5,000,000 | 3.31M | Sep 29, 2024 |
| Vivo Capital, LLC | 4.31% | 4,470,152 | 2.96M | Sep 29, 2024 |
| SilverArc Capital Management, LLC | 3.85% | 4,000,000 | 2.65M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.74% | 765,000 | 507.19K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.36% | 373,220 | 247.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.22% | 229,420 | 152.10K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 71,488 | 47.40K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.06% | 65,366 | 43.34K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 54,032 | 35.82K | Oct 30, 2024 |
